SCHEMBL190479

SCHEMBL190479

CCOC(=O)Cc1ccnc(C(=O)OC(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
GABRA1 P14867 5/20 0.38
GABRG2 P18507 5/20 0.38
GABRB3 P28472 5/20 0.38
GABRA3 P34903 5/20 0.38
GABRA2 P47869 5/20 0.38
GABRA5 P31644 4/20 0.38
GABRA4 P48169 3/20 0.38
GABRA6 Q16445 3/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15561762 0.80 SLC7A5 (0.46) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL27459696 0.80 JMJD6 (0.50) SMN1; SMN2LMNANPC1RAB9A
SCHEMBL27741183 0.79 GABRG2 (0.42) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL7108957 0.79 LOXL2 (0.51) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL14595539 0.79 GABRG2 (0.43) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL190869 0.79 IGF1R (0.44) SMN1; SMN2LMNAMAPTL3MBTL1NPC1
SCHEMBL7358842 0.79 POLB (0.47) SMN1; SMN2LMNAMAPTL3MBTL1GABRA1
SCHEMBL933096 0.78 GLS (0.41) SMN1; SMN2LMNAMAPTL3MBTL1NPC1
SCHEMBL4420980 0.77 SMN1; SMN2 (0.45) SMN1; SMN2LMNAMAPTL3MBTL1NPC1
SCHEMBL13653554 0.76 CDC7 (0.49) SMN1; SMN2LMNAMAPTL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 SMN1; SMN2 2600/4885LMNA 1829/4885MAPT 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.